Head to Head Review: Praxis Precision Medicines (NASDAQ:PRAX) vs. Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ:LSTA) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Insider & Institutional Ownership

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Lisata Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lisata Therapeutics and Praxis Precision Medicines”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170,000.00	56.18	-$16.59 million	($1.64)	-0.65
Praxis Precision Medicines	$8.55 million	848.57	-$303.27 million	($12.93)	-20.10

Lisata Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lisata Therapeutics and Praxis Precision Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Analyst Recommendations

This is a breakdown of current recommendations for Lisata Therapeutics and Praxis Precision Medicines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	2	0	0	1.67
Praxis Precision Medicines	2	0	15	3	2.95

Praxis Precision Medicines has a consensus price target of $613.26, suggesting a potential upside of 136.00%. Given Praxis Precision Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Lisata Therapeutics.

Summary

Praxis Precision Medicines beats Lisata Therapeutics on 10 of the 14 factors compared between the two stocks.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.